ES2111617T3 - Derivados de pirimidina condensados y su utilizacion como antagonistas de la angiotensina ii. - Google Patents

Derivados de pirimidina condensados y su utilizacion como antagonistas de la angiotensina ii.

Info

Publication number
ES2111617T3
ES2111617T3 ES92309333T ES92309333T ES2111617T3 ES 2111617 T3 ES2111617 T3 ES 2111617T3 ES 92309333 T ES92309333 T ES 92309333T ES 92309333 T ES92309333 T ES 92309333T ES 2111617 T3 ES2111617 T3 ES 2111617T3
Authority
ES
Spain
Prior art keywords
angiotensin
antagonists
condensed
pirimidine derivatives
pirimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92309333T
Other languages
English (en)
Spanish (es)
Inventor
John Watson Ellingboe
Madelene Nikaido
Jehan Franroz Bagli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/782,025 external-priority patent/US5149699A/en
Priority claimed from GB9207560A external-priority patent/GB2265899A/en
Priority claimed from US07/901,485 external-priority patent/US5256654A/en
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2111617T3 publication Critical patent/ES2111617T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES92309333T 1991-10-24 1992-10-14 Derivados de pirimidina condensados y su utilizacion como antagonistas de la angiotensina ii. Expired - Lifetime ES2111617T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/782,025 US5149699A (en) 1991-10-24 1991-10-24 Substituted pyridopyrimidines useful as antgiotensin II antagonists
GB9207560A GB2265899A (en) 1992-04-07 1992-04-07 Substituted pyrimidines
US07/901,485 US5256654A (en) 1991-10-24 1992-06-25 Substituted pyrrolopyrimidines, azepinopyrimidines and pyridopyrimidines useful as angiotensin II antagonists

Publications (1)

Publication Number Publication Date
ES2111617T3 true ES2111617T3 (es) 1998-03-16

Family

ID=27266132

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92309333T Expired - Lifetime ES2111617T3 (es) 1991-10-24 1992-10-14 Derivados de pirimidina condensados y su utilizacion como antagonistas de la angiotensina ii.

Country Status (20)

Country Link
EP (1) EP0539086B1 (en:Method)
JP (1) JP3240192B2 (en:Method)
KR (1) KR100286624B1 (en:Method)
CN (2) CN1039324C (en:Method)
AT (1) ATE161537T1 (en:Method)
AU (1) AU653635B2 (en:Method)
CA (1) CA2080705C (en:Method)
DE (1) DE69223734T2 (en:Method)
DK (1) DK0539086T3 (en:Method)
ES (1) ES2111617T3 (en:Method)
FI (1) FI103971B (en:Method)
GR (1) GR3025926T3 (en:Method)
HU (2) HU218786B (en:Method)
IL (1) IL103436A (en:Method)
LV (1) LV12047B (en:Method)
NO (1) NO301275B1 (en:Method)
SG (1) SG47626A1 (en:Method)
SK (1) SK280292B6 (en:Method)
TW (1) TW226375B (en:Method)
UA (1) UA27748C2 (en:Method)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233208T2 (de) * 1991-11-18 2004-07-08 E.I. Du Pont De Nemours And Co., Wilmington Tetrazolylphenylborsäureintermediate zur synthese von aii rezeptor antagonisten
EP0618207B1 (en) * 1993-03-24 1999-01-07 American Home Products Corporation Substituted pyridopyrimidines as antihypertensives
WO1996009301A1 (en) * 1994-09-20 1996-03-28 Wakunaga Seiyaku Kabushiki Kaisha Process for producing n-biphenylmethylthiadiazoline derivative or salt thereof and intermediate for producing the same
IT1292437B1 (it) * 1997-06-30 1999-02-08 Zambon Spa Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
PE20020617A1 (es) 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
WO2005089731A2 (en) 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
CA2580862A1 (en) 2004-10-08 2006-04-20 Novartis Ag Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
EP1749828A1 (en) 2005-08-04 2007-02-07 Farmaprojects S.L. Process for preparing an angiotensin II receptor antagonist
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
HUE025599T2 (en) * 2007-06-07 2016-05-30 Sigma Tau Ind Farmaceuti 5ß, 14β-androstane derivatives for treating diseases caused by organ fibrosis
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
NZ598685A (en) 2009-09-11 2013-05-31 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
AP2014007766A0 (en) 2011-12-15 2014-07-31 Takeda Pharmaceuticals Usa Inc Combination os azilsartan and chlorthlidone for treating hypertension black patients
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
US5100897A (en) * 1989-08-28 1992-03-31 Merck & Co., Inc. Substituted pyrimidinones as angiotensin ii antagonists
EP0415886A3 (en) * 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
CA2075637A1 (en) * 1990-02-13 1991-08-14 William J. Greenlee Angiotensin ii antagonists incorporating a substituted benzyl element
IL100917A0 (en) 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
US5149699A (en) * 1991-10-24 1992-09-22 American Home Products Corporation Substituted pyridopyrimidines useful as antgiotensin II antagonists

Also Published As

Publication number Publication date
DE69223734D1 (de) 1998-02-05
LV12047B (en) 1998-08-20
FI103971B1 (fi) 1999-10-29
EP0539086A3 (en) 1993-06-16
HU218786B (hu) 2000-12-28
NO924121L (no) 1993-04-26
UA27748C2 (uk) 2000-10-16
KR100286624B1 (ko) 2001-05-02
GR3025926T3 (en) 1998-04-30
FI103971B (fi) 1999-10-29
EP0539086A2 (en) 1993-04-28
SG47626A1 (en) 1998-04-17
SK322192A3 (en) 1999-11-08
HU9203161D0 (en) 1992-12-28
JPH05222039A (ja) 1993-08-31
TW226375B (en:Method) 1994-07-11
FI924397L (fi) 1993-04-25
CA2080705C (en) 2002-12-03
FI924397A0 (fi) 1992-09-30
JP3240192B2 (ja) 2001-12-17
IL103436A0 (en) 1993-03-15
DK0539086T3 (da) 1998-02-02
HUT62893A (en) 1993-06-28
CN1039324C (zh) 1998-07-29
KR930007949A (ko) 1993-05-20
HU211915A9 (en) 1996-01-29
SK280292B6 (sk) 1999-11-08
HK1003031A1 (en) 1998-09-30
CA2080705A1 (en) 1993-04-25
IL103436A (en) 1996-03-31
CN1072682A (zh) 1993-06-02
CN1175414A (zh) 1998-03-11
NO301275B1 (no) 1997-10-06
LV12047A (lv) 1998-05-20
DE69223734T2 (de) 1998-04-16
NO924121D0 (no) 1992-10-23
AU653635B2 (en) 1994-10-06
EP0539086B1 (en) 1997-12-29
AU2607992A (en) 1993-04-29
ATE161537T1 (de) 1998-01-15

Similar Documents

Publication Publication Date Title
ES2111617T3 (es) Derivados de pirimidina condensados y su utilizacion como antagonistas de la angiotensina ii.
PT1005453E (pt) Compostos de benzeno substituido como agentes de reducao antiproliferativa
CY1107475T1 (el) Αναστολεις ρο-κινασης
ES2114882T3 (es) Acidos hidroxialquilquinolinos insaturados como antagonistas de leucotrienos.
BR9710737A (pt) Pentafluorobenzenosulfonamidas e análogos.
BR9810366A (pt) Derivados de ácido 4-bromo ou 4-iodo fenilamino benzidroxîmico e seu uso como inibidores de mek
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
ES2172585T3 (es) Derivado de benzoimidazol.
BR0002518A (pt) Derivados de 4-arilpiperidina para o tratamento de prurido
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
ES2052463T1 (es) Antihipercolesterolemicos.
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
MX9606494A (es) Compuestos organicos.
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
MX9307047A (es) Compuestos de quinazolinas y bencimidazoles substituidos.
UY26498A1 (es) Pirroles sustituidos
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
DE60106014D1 (de) Verwendung von n,n'-dibenzylethylendiamindiessigsäurederivaten zum schutz gegen verschmutzung
DK0522001T3 (da) Understøttende anvendelse af Linomide
ES2159087T3 (es) Oxindoles sustituidos con adamantilo como agentes farmaceuticos.
ECSP972204A (es) Pirroles sustituidos
ATE360432T1 (de) Peptid zur behandlung von nervenerkrankungen
CY1105506T1 (el) Διαμιδια τα οποια αναστελλουν τη δραση της θρυπτασης και του παραγοντα χα

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 539086

Country of ref document: ES